PYP Scintigraphy Visual Score Calculator

Clinical calculation support · Verify results before clinical use

Visual grading

Select the myocardial uptake grade relative to rib uptake on the imaging study.

— Grade

Choose one grade based on interpretation of the planar images together with SPECT or SPECT/CT. This calculator supports reporting and does not independently establish a diagnosis.

0Grade

No myocardial uptake

No cardiac uptake with preserved normal bone uptake.

1Grade

Mild myocardial uptake

Myocardial uptake is present but less than rib uptake; this is an equivocal result.

2Grade

Moderate myocardial uptake

Myocardial uptake is equal to rib uptake. Confirm that activity is truly myocardial on SPECT/SPECT-CT and not blood-pool activity.

3Grade

High myocardial uptake

Myocardial uptake is greater than rib uptake, often with reduced or absent rib uptake.

— Visual grade
Imaging interpretation

Select a grade to view interpretation

The result will appear here after a grade is selected.

Clinical context and next steps

Select a grade. Interpret the scan alongside clinical assessment and the complete diagnostic work-up.

A visual grade is an imaging descriptor, not a stand-alone diagnosis. Always verify myocardial localization on SPECT/SPECT-CT and assess for a monoclonal protein when evaluating suspected cardiac amyloidosis.

How to interpret the visual grade

The 99mTc-pyrophosphate (PYP) visual score compares myocardial tracer uptake with rib uptake. It is used as part of the evaluation for transthyretin cardiac amyloidosis (ATTR-CM), not as a substitute for the full diagnostic pathway.

GradeRelative uptakeImaging category
0No myocardial uptake; normal bone uptakeNot suggestive on PYP imaging
1Myocardial uptake less than ribsEquivocal
2Myocardial uptake equal to ribsPositive pattern, if myocardial uptake is confirmed
3Myocardial uptake greater than ribs, often with reduced/absent rib uptakePositive pattern, if myocardial uptake is confirmed

Important diagnostic safeguards

  • Use SPECT or SPECT/CT to confirm myocardial uptake and distinguish it from blood-pool activity or overlapping structures.
  • Grades 2–3 support a nonbiopsy diagnosis of ATTR-CM only when the clinical/imaging context is compatible and AL amyloidosis has been excluded with appropriate testing.
  • Screening for a monoclonal protein generally includes serum free light chains plus serum and urine immunofixation. If any test is abnormal, specialist evaluation and tissue confirmation may be required.
  • A grade 0 scan does not exclude every form of cardiac amyloidosis, including AL amyloidosis, and further assessment may be appropriate when suspicion remains high.

References

Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404–2412. doi:10.1161/CIRCULATIONAHA.116.021612. PMID: 27143678.
American Society of Nuclear Cardiology (ASNC). 99mTechnetium-Pyrophosphate Imaging for Transthyretin Cardiac Amyloidosis: Practice Points. Updated practice point. ASNC practice points.
Taiwan Society of Cardiology and Society of Nuclear Medicine of the Republic of China. 2025 Update Consensus of 99mTc-Pyrophosphate Scintigraphy in the Transthyretin Cardiac Amyloidosis. Full text (PMC).
American College of Cardiology. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis. Consensus document.
Clinical disclaimer: This tool is intended to support education and structured interpretation. It does not diagnose ATTR-CM, exclude AL amyloidosis, or replace nuclear medicine reporting, monoclonal protein testing, specialist assessment, or local protocols. Interpret results in the context of image quality, acquisition timing, SPECT/SPECT-CT findings, clinical probability, and other investigations.